Response
Over the years, Dr Pibarot and colleagues have contributed enormously to our understanding of prosthesis-patient mismatch. We agree that the term prosthesis-patient size should be reserved for expressing the continuous relation of prosthesis dimensions, however expressed, to body size, as proposed previously. 1, 2 We disagree that prosthesis-patient mismatch is fundamentally a hemodynamic concept; originally, it referred to a clinical syndrome. 3 Semantics aside, readers need to understand our long-standing differences in perspective about the clinical importance of prosthesis size.
1, A few patients manifest a clinical syndrome after aortic valve replacement (AVR) that is relieved by inserting a larger prosthesis. 3 This is true prosthesis-patient mismatch syndrome, not an arbitrary dichotomous characterization of hemodynamics. 2, Within the constraints of prudent AVR, it is difficult to demonstrate a relationship between long-term survival and physical prosthesis dimensions. 1 
3, Life expectancy after AVR does not return to normal, except
in the elderly, who tend to receive small prostheses. 1 This suggests a complex relationship between prosthesis size and clinical outcome, including genetic factors, 4 secondary cardiomyopathy, afterload reduction by AVR, post-AVR left ventricular outflow tract (LVOT) dynamics, aorta, and intrinsic properties of the prosthesis. 4, Calculated effective orifice area (EOA) and pressure gradient are of necessity well correlated because they are derived from the same primary echocardiographic velocity measurements. 5, EOA is time-varying and depends on many factors besides intrinsic properties of the prosthesis. Attributing complex LVOT energy losses solely to the prosthesis leads to the unproven hypothesis that simply inserting a large-size prosthesis will improve clinical outcome. Understanding the implications of this attribution is important when considering percutaneous AVR.
In our view, with so little evidence that prosthesis size makes a substantial impact on long-term mortality and quality of life, it is time to identify other factors that might be more important in improving outcomes after AVR.
